ABOS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.430

-30.65%

-0.380

-20.83%

-0.363

-46.57%

Estimates Revision

Stock Price

Go Down

-2.93%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast ABOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABOS is 6.50 USD with a low forecast of 4.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

4.00

Averages

6.50

High

10.00

Current: 0.000

Low

4.00

Averages

6.50

High

10.00

Lucid Capital

NULL -> Buy

initiated

2025-12-17

Reason

Lucid Capital

Price Target

2025-12-17

initiated

NULL -> Buy

Reason

Lucid Capital initiated coverage of Acumen with a Buy rating and $6 price target. The firm says Acumen is developing sabirnetug, an anti-amyloid beta oligomer monoclonal antibody that targets the most neurotoxic species in Alzheimer's disease. The compound has demonstrated "compelling" Phase 1 proof-of-mechanism data, the analyst tells investors in a research note. Lucid sees a "meaningful near-term value inflection" with the Phase 2 ALTITUDE-AD results expected in late 2026.

BofA

Buy

downgrade

$9 -> $8

2025-11-18

Reason

BofA

Price Target

$9 -> $8

2025-11-18

downgrade

Buy

Reason

BofA lowered the firm's price target on Acumen to $8 from $9 and keeps a Buy rating on the shares, citing an updated cash position following the company's Q3 update.

BTIG

Thomas Shrader

Buy

downgrade

$11 -> $4

2025-10-16

Reason

BTIG

Thomas Shrader

Price Target

$11 -> $4

2025-10-16

downgrade

Buy

Reason

BTIG analyst Thomas Shrader lowered the firm's price target on Acumen to $4 from $11 and keeps a Buy rating on the shares. In a broader research note previewing Q3 results for select biotech names, the firm is updating its assumptions and models for the company, the analyst tells investors in a research note.

BofA

Buy

maintain

$10 -> $9

2025-08-25

Reason

BofA

Price Target

$10 -> $9

2025-08-25

maintain

Buy

Reason

BofA lowered the firm's price target on Acumen to $9 from $10 and keeps a Buy rating on the shares, citing the updated cash position following a Q2 report the firm calls "(understandably) quiet." The "key update" was the phase 2 ALTITUDE-AD of sabirnetug in early AD remains on track to read-out late 2026, the analyst added.

Citi

Buy

initiated

2025-06-18

Reason

Citi

Price Target

2025-06-18

initiated

Buy

Reason

Citi initiated coverage of Acumen (ACUM) with a Buy rating and $4 price target. Acumen is a clinical stage biotech company currently developing sabirnetug for the treatment of Alzheimer's disease by selectively targeting toxic AN2 oligomers, the analyst tells investors in a research note. The firm says Acumen is utilizing a novel approach by only attacking toxic AN2 oligomers with IV sabirnetug, whereas other companies' monoclonal antibodies target other less-toxic AN2O species such as monomers, protofibrils or mature plaques. It believes the company has generated "early yet promising" Phase 1 data, which suggests sabirnetug reduces amyloid plaques at a similar rate and magnitude to Biogen's (BIIB) Leqembi at comparable time points, alongside a safety profile that betters current on-the-market therapies. Citi views the large unmet need in Alzheimer's as a space that can hold multiple players including sabirnetug.

HC Wainwright & Co.

Andrew Fein

Strong Buy

Maintains

$15 → $11

2025-03-28

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$15 → $11

2025-03-28

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Acumen Pharmaceuticals Inc (ABOS.O) is -1.32, compared to its 5-year average forward P/E of -7.12. For a more detailed relative valuation and DCF analysis to assess Acumen Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.12

Current PE

-1.32

Overvalued PE

6.64

Undervalued PE

-20.88

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.06

Current EV/EBITDA

-0.14

Overvalued EV/EBITDA

5.26

Undervalued EV/EBITDA

-9.39

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

112.41

Current PS

0.00

Overvalued PS

575.41

Undervalued PS

-350.58

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ABOS News & Events

Events Timeline

No data

News

2.0

01-06NASDAQ.COM

Alumis Inc. (ALMS) Shares Surge 17.33% on Phase 3 Clinical Trial Data Announcement

2.0

2025-12-08NASDAQ.COM

Healthcare Stocks Surge in After-Hours Trading: KYMR, OCUL, POAI Lead the Gains

9.5

2025-11-12Newsfilter

Acumen Pharmaceuticals Announces Financial Results and Business Highlights for Q3 2025

People Also Watch

Frequently Asked Questions

What is Acumen Pharmaceuticals Inc (ABOS) stock price today?

The current price of ABOS is 1.825 USD — it has decreased -8.29 % in the last trading day.

What is Acumen Pharmaceuticals Inc (ABOS)'s business?

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in its Phase II ALTITUDE-AD clinical trial following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to AD). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer, has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic mouse models for AD. The Company is developing sabirnetug for IV administration once every four weeks (Q4W) for the treatment of early AD, and it has developing sabirnetug for subcutaneous administration.

What is the price predicton of ABOS Stock?

What is Acumen Pharmaceuticals Inc (ABOS)'s revenue for the last quarter?

Acumen Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Acumen Pharmaceuticals Inc (ABOS)'s earnings per share (EPS) for the last quarter?

Acumen Pharmaceuticals Inc. EPS for the last quarter amounts to -0.44 USD, decreased -12.00 % YoY.

What changes have occurred in the market's expectations for Acumen Pharmaceuticals Inc (ABOS)'s fundamentals?

The market is revising No Change the revenue expectations for ABOS for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -2.93%.

How many employees does Acumen Pharmaceuticals Inc (ABOS). have?

Acumen Pharmaceuticals Inc (ABOS) has 61 emplpoyees as of January 08 2026.

What is Acumen Pharmaceuticals Inc (ABOS) market cap?

Today ABOS has the market capitalization of 119.94M USD.